Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01024686 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine
A Phase 1 study, sponsored by Seattle Children's Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01024686 is a Phase 1 study that was terminated before completion, run by Seattle Children's Hospital. The registered enrollment target is 6 participants.
The verdict
NCT01024686, a Phase 1 study, was terminated before completion, sponsored by Seattle Children's Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety and tolerability of escalating doses of a genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy malaria-naive adults. The study will also assess preliminary efficacy of p52-/p36- GAP vaccine following primary experimental challenge with P. falciparum sporozoites. Lastly, the study will assess immunogenicity of p52-/p36- GAP in malaria-naïve healthy adults and preliminary efficacy of p52-/p36- GAP vaccine following primary experimental re-challenge with P. falciparum sporozoites.
Interventions
- BIOLOGICAL p52-/p36- GAP Vaccine
- BIOLOGICAL p52-p36- GAP Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01024686
The ClinicalTrials.gov registry entry for NCT01024686 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which p52-/p36- GAP Vaccine is the first listed.
NCT01024686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01024686 about?
NCT01024686 is a clinical study titled "Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine". The purpose of this study is to assess safety and tolerability of escalating doses of a genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy malaria-naive adults. The study will also assess preliminary efficacy of p52-/p36- GAP vaccine following primary experimental cha...
What is the current status of trial NCT01024686?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2010-03. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01024686?
The interventions under investigation include: p52-/p36- GAP Vaccine (BIOLOGICAL), p52-p36- GAP Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01024686?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.